Bortezomib

Bortezomib, sold under the brand name Velcade among others, is an anti-cancer medication used to treat multiple myeloma and mantle cell lymphoma.<ref name="a2">[https://www.drugs.com/monograph/bortezomib.html "Bortezomib Monograph for Professionals".] Drugs.com. Retrieved 13 October 2019.</ref> This includes multiple myeloma in those who have and have not previously received treatment. It is generally used together with other medications.<ref name="a3">[https://www.ema.europa.eu/en/medicines/human/EPAR/velcade "Velcade".] European Medicines Agency (EMA). 17 September 2018. Retrieved 13 October 2019.</ref> See also [https://en.wikipedia.org/wiki/Bortezomib Bortezomib].

Bortezomib is an N-protected dipeptide and can be written as <scene name='10/1022872/Cv/2'>Pyz-Phe-boroLeu</scene>, which stands for <scene name='10/1022872/Cv/3'>pyrazinoic acid, phenylalanine and Leucine with a boronic acid</scene> instead of a carboxylic acid.